Proton pump inhibitors are not associated with inflammatory myopathies: A case control study.

ABSTRACT

INTRODUCTION: A rare association of proton pump inhibitor (PPI) use with the development of inflammatory myopathies (IM) has been reported, but, unlike with statin medications, there is limited data supporting or refuting this observation. METHODS: A case-control study was conducted on patients with IM. Clinical information, medications, and demographics were recorded. Controls were matched 31 for age and gender. RESULTS: Two hundred twenty-one cases of IM were identified. No association of PPI use with IM was observed when compared with controls (odds ratio 1.04 [95% confidence interval 0.68-1.58]) and similar results were observed after adjusting for diabetes, cardiovascular disease, and statin exposure (adjusted odds ratio 1.084 [95% confidence interval 0.69-1.70]). There was no association of any histologic subtype of IM with PPI exposure. DISCUSSION: Our findings do not support an association of PPI exposure with IM. Co-prescription of PPI with other medications was not considered and could be further investigated with larger cohorts. Muscle Nerve 58855-857, 2018.